EDITOR’S NOTE: I was supposed to be a patient advocate and an editor. This week the patient took over and it seems my mouse, keyboard and brain had a small rebellion. This issue’s is a a little short on 1 of our favorite parts, Creating.

For you- Hizentra offers steady weekly dosing at home; HyQvia combines Ig with hyaluronidase to allow larger volumes every 3–4 weeks. Choice depends on lifestyle, venous access, tolerance, and payer rules.

“Can I move my CIDP maintenance to at-home SCIG?”
Why it matters: Fewer clinic trips + steadier IgG levels.
Start here: Hizentra CIDP label (FDA, 2021) | HyQvia CIDP label (FDA, 2023)

“If I start ravulizumab for AQP4+ NMOSD, which meningococcal shots do I need?”
Why it matters: Complement blockers increase meningitis risk; vaccines + counseling are required.
Start here: Ravulizumab label (FDA, approved March 2024); CDC meningococcal guidance (2025 update)

“MOGAD vs NMOSD — what test really separates them?”
Why it matters: Treatment and prognosis differ.
Start here: NORD overview on MOGAD (Oct 2025) + peer-reviewed comparative reviews (2024–2025)

“Any Texas clinics that actually see neuro-immunology patients?”
Why it matters: Shorter waitlists and local referrals.
Start here: UT Southwestern Neuroimmunology (Dallas) | UTHealth Houston Neuroimmunology/MS division

“We’re hours from a center—who helps with rides?”
Why it matters: Missed appointments = worse outcomes.
Start here: Texas Medical Transportation Program (NEMT) ☎ 877-633-8747

“Is there financial help for CIDP costs?”
Why it matters: Copays and premiums add up.
Start here: NORD CIDP Patient Assistance Program via the GBS-CIDP Foundation

“Peer support near me?”
Why it matters: Shared tips = stronger coping.
Start here: GBS-CIDP Foundation Support Groups (2025 directory)

Home-based SCIG for CIDP — weekly vs every 4–8 weeks

Subcutaneous immunoglobulin for CIDP is established, but many Texans ask how Hizentra (weekly) compares with HyQvia (less frequent). Both carry FDA-recognized CIDP indications (2021 and 2023) but differ in frequency and setup. Hizentra offers steady weekly dosing at home; HyQvia combines Ig with hyaluronidase to allow larger volumes every ~3–4 weeks. The right fit depends on lifestyle, venous access, tolerance, and payer rules.

Why it matters in Texas
• Fewer miles along I-35 and I-45
• Flexibility for working caregivers
• Different pharmacokinetics and side-effect profiles—ask your neurology team to map pros/cons before switching

CIDP — Phase 4 “Transition” to efgartigimod PH20 SC
• ClinicalTrials.gov ID: NCT06637072
• Design: Open-label (~17–19 weeks). Transition from IVIg to efgartigimod SC after ~1-week gap
• Texas: Multi-site U.S.; check current Texas site status by searching the NCT ID
• Eligibility: Adults with CIDP on stable IVIg
• Sources: CT.gov record (by NCT), AAN 2025 poster, Neurology trial brief (references only)

CIDP — IMVT-1402 (FcRn inhibitor)
• Status: U.S. sites recruiting; verify Texas availability by searching “IMVT-1402” or the NCT ID when posted
• Note: Sponsor (Immunovant) transitioned portfolio emphasis from batoclimab to IMVT-1402 in 2025
• Sources: RareDiseaseAdvisor coverage; sponsor statements (2025) (references only)

🗓 Tip: Trial rosters change quickly—always search the NCT number and check the “last updated/verified” date before calling a site.

• UTHealth Houston Neurosciences (Texas Medical Center) — Neuroimmunology/MS division
Appointments: 832-325-7080
• UT Southwestern Neuroimmunology (Dallas/Aston) — patient access lines listed via main
Main: 214-645-8800
• Houston Methodist Neuromuscular Clinic (TMC) — info line
713-363-7310
• Travel help (Medicaid/CHIP): Texas NEMT (MED-TRIP) 877-633-8747

• “Which SCIG schedule (weekly vs monthly-ish) best fits my work/travel, and how will we monitor IgG levels and neuropathy scores?”
• “If starting ravulizumab, can we plan MenACWY + MenB vaccine timing and REMS steps before first infusion?”
• “Given my features, do I fit MOGAD vs NMOSD—and which lab should run AQP4-IgG and MOG-IgG testing?”

At-home maintenance now includes FDA-recognized SCIG options: weekly (Hizentra) and less-frequent (HyQvia). Match schedule to fatigue, distance, and coverage.

SCIG — Under-the-skin immunoglobulin therapy offering steadier IgG levels and home administration.
FcRn inhibitor — Drug class that lowers IgG by blocking the neonatal Fc receptor (e.g., IMVT-1402).
REMS — Risk Evaluation and Mitigation Strategy; FDA-required safety program for certain higher-risk medications (e.g., ravulizumab).

• Hizentra & HyQvia (CIDP) — FDA-recognized indications: 2021 (Hizentra) and 2023 (HyQvia).
• Ravulizumab for AQP4+ NMOSD — FDA-approved March 2024; requires MenACWY + MenB vaccination and REMS enrollment/counseling.
• MOGAD overview — NORD refreshed Oct 2025; multiple 2024–2025 comparative reviews distinguish MOGAD vs NMOSD testing and care.
• Texas clinic contacts and NEMT numbers verified Nov 2025.
• Trials — NCT identifiers provided; readers search by NCT to avoid link breakage.

Need a laugh after all this science? Our sister newsletter keeps the humor alive in rare neuro—because sometimes laughter is the best co-therapy.

📧 Trusted admin email: [email protected]

Educational only—this is not medical advice. Always consult your clinician before making treatment decisions. Clinical-trial info is for education; eligibility and enrollment must be discussed with qualified professionals.

Mission-aligned sponsors help expand access, education, and community support without influencing editorial coverage. For collaboration info, email [email protected].